Study agents | Other agents | Disease | Dosage | Clinical trials | No. of Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Ofatumumab | Â | Untreated | 2000/1000Â mg | Phase II | 77 | CR:5/4% | [28] |
 |  |  |  |  |  | ORR:55/36% |  |
Ofatumumab | Lenalidomide | Relapsed | 1000Â mg | Phase II | 36 | CR:24% | [31] |
 |  |  |  |  |  | ORR:68% |  |
Ofatumumab | Lenalidomide | Relapsed | 2000Â mg | Phase II | 17 | ORR:43% | [32] |
 |  | Refractory |  |  |  | SD:21% |  |